Could a delay in the employer mandate be a boost to government run exchanges?

In 2011 we commented that while the health reform law, the ACA, had several positive intended consequences, it also could spawn several perverse effects and side-effects.

Now in an attempt to ward off some of those unintended consequences, the administration has delayed the employer mandate from 2014 to 2015. Reactions range from praise (from the unlikely alliance of Democrats and business groups), derision (from Republicans and right leaning think tanks) and bemusement or befuddlement (across the spectrum).

Of course, perturbing a portion of a complex system has ripple effects of its own. Here’s one that we’re thinking about. Let’s try it with a logic chain:

1. Employer mandate is postponed to 2015
2. But in 2014 we still have the individual mandate
3. Therefore, some people who would have been covered by their employers (many in defined contribution plans on private exchanges) will end up having to buy coverage as individuals (or doing without and paying the fine, if applicable)
4. Public exchanges (“marketplaces”) have been unsuccessful at attracting employers (Massachusetts for instance has less than 8000 group lives on its “Connector”)
5. But Public exchanges will have a monopoly on most people buying coverage as individuals (certainly on anyone availing of subsidies/ credits)
6. This suggests that an unintended consequence of this change is that it will benefit public exchanges and hurt private exchanges, especially those that are focused on the >50 defined contribution market

I wonder if the idea of supporting pubic exchanges played into the administration’s calculus or if it’s just a serendipitous benefit from their point of view. Either way, I’m sure they’ve thought about it – it’s just not part of the spin.

Share

Keep up with the Recon Strategy Insights

Get an email each time Recon takes an analytical look behind select developments in healthcare.

Suggested Articles

We explore four hypothesized value drivers of platform-based companies and evaluate the actual value achieved 10-15 years out from initial capital raise. We found that discovery platforms showed the highest lead asset success rates, significantly more out-licensing activity than non-platforms, and accounted for nearly all multi-asset approvals within our cohort. All platform types showed increased survivability and more licensing opportunities.
Merck's acquisition of Verona is the latest in a long line of "revenue acquisitions". How have prior mid-size biopharma revenue acquisitions fared? We found that forecasts at the time of deal are often optimistic, with many transactions missing their projected sales trajectories.
The first porcine kidney transplant (in a live recipient) It’s been a year, and like many, I have been waiting for the details to be published in the NEJM (where else – especially since this was done …
We use cookies
This website collects cookies to deliver better user experience and to analyze our website traffic and performance; we never collect any personal data or target you with ads.